Nemes Rush Group’s Biogen BIIB Stock Holding History

Nemes Rush Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$226	Hold	1	–	–	﹤0.01%	919
2026 Q2	$216	Hold	1	–	–	﹤0.01%	938
2026 Q1	$183	Hold	1	–	–	﹤0.01%	923
2025 Q4	$176	Buy	+1	New	+$163	﹤0.01%	936

Other funds holding BIIB

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Nemes Rush Group's BIIB Position: Q3 2026 in Review

Nemes Rush Group held its Biogen (BIIB) position steady in Q3 2026 at 1 share worth $226. The position accounts for ﹤0.01% of the portfolio, ranked #919.

Nemes Rush Group first reported a position in BIIB in Q4 2025 and has held it in 4 quarters since. 532 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

Nemes Rush Group held 1 share of Biogen worth $226 as of Q3 2026.
Nemes Rush Group left its Biogen share count unchanged in Q3 2026.
Biogen made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #919 holding.
Nemes Rush Group first reported a position in Biogen in Q4 2025 and has held it in 4 quarters since.
532 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.